Aardvark Therapeutics (NASDAQ:AARD) Now Covered by Analysts at Bank of America

Analysts at Bank of America assumed coverage on shares of Aardvark Therapeutics (NASDAQ:AARD) in a research note issued to investors on Monday,Briefing.com Automated Import reports. The brokerage set a “buy” rating and a $22.00 price target on the stock. Bank of America‘s price target indicates a potential upside of 117.18% from the company’s current price.

A number of other analysts also recently issued reports on AARD. Royal Bank of Canada initiated coverage on Aardvark Therapeutics in a research report on Monday. They issued an “outperform” rating and a $21.00 target price on the stock. Cantor Fitzgerald initiated coverage on Aardvark Therapeutics in a research report on Monday. They issued an “overweight” rating and a $50.00 target price on the stock.

Aardvark Therapeutics Price Performance

NASDAQ:AARD opened at $10.13 on Monday. Aardvark Therapeutics has a 52-week low of $9.21 and a 52-week high of $19.58.

Insiders Place Their Bets

In other Aardvark Therapeutics news, CFO Nelson Sun purchased 10,000 shares of the stock in a transaction on Friday, February 14th. The shares were purchased at an average price of $16.00 per share, with a total value of $160,000.00. Following the completion of the transaction, the chief financial officer now directly owns 99,484 shares in the company, valued at $1,591,744. This represents a 11.18 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Tien-Li Lee purchased 16,542 shares of the stock in a transaction on Friday, February 14th. The shares were acquired at an average cost of $16.00 per share, for a total transaction of $264,672.00. Following the transaction, the chief executive officer now owns 1,496,175 shares of the company’s stock, valued at approximately $23,938,800. The trade was a 1.12 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

About Aardvark Therapeutics

We are a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. We target biological pathways associated with alleviating hunger that we believe have the potential to deliver transformative outcomes for patients.